Stomach disorder
MONDO:0004298A disease involving the stomach.
Also known as: disease of stomach, disease or disorder of stomach, disorder of stomach, stomach disease, stomach disease or disorder, stomach disorder
1378 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
Could a common ED drug boost chemo for stomach cancer?
Disease control OngoingThis study tests whether adding tadalafil (a drug used for erectile dysfunction) to standard chemotherapy can help shrink stomach or gastroesophageal junction tumors before surgery. Ten adults with resectable cancer will receive tadalafil alone for two weeks, then combined with c…
Phase: PHASE2 • Sponsor: University of Arizona • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Experimental drug duo targets Hard-to-Treat HER2 cancers
Disease control OngoingThis study tests two drugs together—disitamab vedotin and tucatinib—in people with advanced breast or stomach cancers that have a protein called HER2. The goal is to see if the combination is safe and shrinks tumors. About 172 participants will take part.
Phase: PHASE2 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New drug targets Hard-to-Treat cancer mutation in first human trial
Disease control OngoingThis study tests a new drug called ARV-806 in adults with advanced solid tumors that have a specific KRAS G12D mutation. The drug aims to break down the mutated protein that helps tumors grow. The trial has two parts: first, finding a safe dose in small groups, then testing that …
Phase: PHASE1, PHASE2 • Sponsor: Arvinas Inc. • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New hope for advanced stomach cancer: drug cocktails under trial
Disease control OngoingThis study tests whether combining new drugs with or without chemotherapy can safely control advanced stomach, GEJ, or esophageal cancer. About 332 adults with inoperable or metastatic disease will receive different treatment combinations. The goal is to find more effective optio…
Phase: PHASE2 • Sponsor: Arcus Biosciences, Inc. • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New cancer drug AB598 enters first human tests
Disease control OngoingThis early-phase trial is testing an experimental drug called AB598, alone or with other cancer drugs, in 40 people with advanced solid tumors like lung, bladder, or breast cancer. The main goal is to check safety and find the right dose. It is not yet known if the drug helps shr…
Phase: PHASE1 • Sponsor: Arcus Biosciences, Inc. • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New combo therapy targets Hard-to-Treat stomach cancers in Mid-Stage trial
Disease control OngoingThis phase II trial is testing whether adding chemotherapy to the immunotherapy drug atezolizumab works better than atezolizumab alone for patients with a specific genetic type of stomach or gastroesophageal junction cancer (MSI-H/dMMR). The study involves 240 adults with localiz…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Could an allergy drug tame rare stomach inflammation?
Disease control OngoingThis study tests dupilumab, an injectable drug already used for allergies, in 22 adults and teens with eosinophilic gastritis (stomach inflammation caused by too many white blood cells). The goal is to see if it reduces inflammation and improves symptoms over 6 months to a year. …
Phase: PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New drug cocktail aims to fight stomach cancer in the abdomen
Disease control OngoingThis early-phase trial tests whether adding an immune-boosting drug (aldesleukin) to standard chemotherapy and another immunotherapy (nivolumab) can help control stomach cancer that has spread to the lining of the abdomen. About 15 adults with this advanced cancer will receive th…
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New hope for advanced stomach cancer: experimental combo targets HER2-positive tumors
Disease control OngoingThis study tests whether a new drug called zanidatamab, combined with chemotherapy and sometimes another drug (tislelizumab), works better than the current standard treatment for advanced HER2-positive stomach and esophageal cancers. About 920 adults whose cancer has spread or ca…
Phase: PHASE3 • Sponsor: Jazz Pharmaceuticals • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New drug combo tested for tough cancers
Disease control OngoingThis early-stage trial tests a new drug called remzistotug, alone or with other cancer drugs, in 152 people with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and find the right dose. It is not yet known if the drug will sh…
Phase: PHASE1 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Triple therapy aims to outsmart stomach cancer
Disease control OngoingThis Phase 3 trial tests whether adding two immunotherapy drugs (nivolumab and ipilimumab) to standard chemotherapy helps people with advanced HER2-negative stomach or gastroesophageal junction cancer live longer. About 626 participants who have not had prior chemotherapy will re…
Phase: PHASE3 • Sponsor: Ono Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug combo aims to tackle Hard-to-Treat cancers
Disease control OngoingThis trial tests an experimental drug called TRK-950 in combination with several standard anti-cancer treatments for people with advanced solid tumors, including colorectal, bladder, ovarian, and other cancers. The main goal is to find safe doses and understand side effects. Part…
Phase: PHASE1 • Sponsor: Toray Industries, Inc • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New antibody drug takes on advanced tumors in first human trial
Disease control OngoingThis early-phase trial tests an experimental drug called IPH5301, which targets a protein called CD73 on cancer cells. The study involves 27 people with advanced solid tumors, including breast, lung, and pancreatic cancers. In the first part, IPH5301 is given alone to find a safe…
Phase: PHASE1 • Sponsor: Institut Paoli-Calmettes • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Experimental combo targets Hard-to-Treat esophageal cancer
Disease control OngoingThis early-stage trial tested a drug called adavosertib together with radiation therapy for people with advanced esophageal or stomach cancer that cannot be surgically removed. The goal was to find the safest dose and see how well the combination works. Only 4 people took part, s…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New drug combo shows promise for hard-to-treat stomach cancer
Disease control OngoingThis study tests a drug called zolbetuximab that targets a protein (CLDN18.2) found in many stomach and gastroesophageal junction tumors. The drug is given alone or with chemotherapy and/or immunotherapy to see how well it controls tumor growth. The study includes 143 adults with…
Phase: PHASE2 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Experimental CAR-T therapy takes on Hard-to-Treat cancers
Disease control OngoingThis early-stage trial tests a new treatment for people with advanced solid tumors that have a specific marker called CLDN6. The treatment uses specially engineered immune cells (CAR-T cells) that target CLDN6, sometimes combined with a genetic booster (RNA-LPX) to enhance their …
Phase: PHASE1 • Sponsor: BioNTech Cell & Gene Therapies GmbH • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Experimental combo targets Hard-to-Treat HER2 cancers
Disease control OngoingThis early-phase trial is testing a combination of two drugs—trastuzumab deruxtecan (a targeted chemotherapy) and ceralasertib (a drug that may block cancer cell repair)—in people with advanced solid tumors that have a HER2 mutation. The study has two parts: first, finding the sa…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Immunotherapy duo takes on rare tumors
Disease control OngoingThis phase 2 trial is testing a combination of two immunotherapy drugs, nivolumab and ipilimumab, in 798 people with over 50 types of rare cancers. The goal is to see if these drugs can shrink tumors by helping the immune system attack cancer cells. Participants receive the drugs…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Radiation plus chemotherapy may boost survival in stomach and esophageal cancer
Disease control OngoingThis phase III trial is testing whether adding radiotherapy to standard chemotherapy improves survival in patients with HER2 negative esophageal or gastric cancer that has spread to a few other spots in the body (oligometastatic). About 314 participants will receive either chemot…
Phase: PHASE3 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New cancer drug candidate BG-68501 enters first human trials
Disease control OngoingThis early-phase study tests a new drug called BG-68501 in people with advanced solid tumors that have not responded to standard treatments. The drug targets a protein (CDK2) that helps cancer cells grow. The trial will check safety, find the right dose, and see if the drug shrin…
Phase: PHASE1 • Sponsor: BeiGene • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug shows promise for Tough-to-Treat stomach cancer
Disease control OngoingThis study tests a new drug called AZD0901 in adults with advanced stomach or gastroesophageal junction cancer that has not responded to prior treatments. The goal is to see if the drug can shrink tumors or slow the cancer's growth. About 33 participants will receive the drug, an…
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Could a Crohn's drug tame a rare stomach disease?
Disease control OngoingThis Phase 2 trial tests whether vedolizumab (Entyvio), a drug used for inflammatory bowel disease, can reduce symptoms of collagenous gastritis—a rare condition causing stomach pain, nausea, and bloating. Eleven participants receive the drug via IV and report their symptoms over…
Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug cocktail shows promise in rare stomach cancer trial
Disease control OngoingThis phase 2 trial is testing whether adding the drug neratinib to a standard combination of chemotherapy, trastuzumab, and pembrolizumab can shrink tumors in people with HER2-positive gastroesophageal cancers. The study includes 8 participants and aims to measure how many respon…
Phase: PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New combo therapy hopes to tame advanced cancers
Disease control OngoingThis early-phase trial tests several new drug combinations in people with advanced solid tumors (like stomach, ovarian, or liver cancer) that have spread and stopped responding to standard treatments. The goal is to find the safest dose and see if the drugs can help control the c…
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control ENROLLING_BY_INVITATIONThis early-phase study tests a new drug called RNDO-564, alone or with pembrolizumab, in adults with advanced solid tumors (like bladder, lung, or breast cancer) that have stopped responding to standard treatments. The main goals are to check safety, find the best dose, and see i…
Phase: PHASE1 • Sponsor: Rondo Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Experimental drug combo targets Hard-to-Treat cancers
Disease control OngoingThis early-phase trial tests an experimental drug called BAY 1895344 combined with standard chemotherapy (cisplatin, with or without gemcitabine) in people with advanced solid tumors, especially urothelial cancer. The goal is to find the best dose and see how safe the combination…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Freezing therapy offers new hope for tough Barrett's cases
Disease control OngoingThis study tests a freezing device (CryoBalloon) to treat Barrett's esophagus that hasn't improved after multiple standard heat treatments. About 70 adults with precancerous changes in the esophagus will receive the freezing therapy. The goal is to safely remove all abnormal tiss…
Phase: NA • Sponsor: University of North Carolina, Chapel Hill • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New drug duo aims to boost immune attack on tough cancers
Disease control OngoingThis early-phase trial tests an experimental drug called HFB200603, either alone or with the immunotherapy tislelizumab, in 83 adults with advanced solid tumors (kidney, lung, melanoma, stomach, or colon cancer). The main goal is to find a safe dose and check for side effects. Re…
Phase: PHASE1 • Sponsor: HiFiBiO Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Magnetic ring for heartburn tracked for 10 years
Disease control OngoingThis registry follows 500 adults who receive the LINX device, a ring of magnetic beads implanted around the esophagus to help keep stomach acid down. The goal is to check for safety issues like device movement, erosion, or swallowing problems over up to 10 years. Participants wil…
Sponsor: Ethicon Endo-Surgery • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Botox injection before hernia surgery may reduce need for risky muscle cuts
Disease control ENROLLING_BY_INVITATIONThis Italian study tests whether injecting Botulinum Toxin A (Botox) into the abdominal muscles weeks before surgery can relax them, making it easier to close large hernias. Researchers will measure changes in CT scans and see if this reduces the need for complex surgical techniq…
Phase: PHASE2 • Sponsor: Azienda Socio Sanitaria Territoriale Ovest Milanese, Ospedale di Legnano • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Engineered immune cells take aim at multiple cancers in early trial
Disease control OngoingThis early-phase study tests a personalized cell therapy for people with certain cancers (bladder, melanoma, head/neck, ovarian, lung, esophageal, stomach, or sarcoma) whose tumors have a specific marker called MAGE-A4. The treatment involves taking a patient's own immune cells, …
Phase: PHASE1 • Sponsor: USWM CT, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Immune cell therapy shows promise for tough cancers
Disease control OngoingThis phase 2 study tests a personalized immune cell therapy called tumor-infiltrating lymphocytes (TIL) in 20 people with advanced solid cancers (like stomach, colon, or pancreatic cancer) that have not responded to standard treatments. Patients first receive chemotherapy to prep…
Phase: PHASE2 • Sponsor: Udai Kammula • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New drug combo aims to outperform standard immunotherapy in stomach cancer
Disease control OngoingThis phase 3 study tests whether a new combination of two immunotherapy drugs (domvanalimab and zimberelimab) plus chemotherapy works better than the current standard (nivolumab plus chemotherapy) for people with advanced stomach, gastroesophageal junction, or esophageal cancer t…
Phase: PHASE3 • Sponsor: Arcus Biosciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Can a diet and lifestyle program replace acid reflux pills after achalasia surgery?
Disease control OngoingThis study tests whether a structured program of dietary changes, lifestyle adjustments, and nutrient correction can reduce reflux symptoms in patients who had POEM surgery for achalasia. Many patients develop GERD after POEM and rely on long-term acid-reducing medications. The t…
Phase: NA • Sponsor: Asian Institute of Gastroenterology, India • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New Dual-Scope surgery shows promise for early stomach cancer
Disease control OngoingThis study tests a new surgery for early gastric cancer that uses two scopes (a laparoscope and an endoscope) to guide the removal of sentinel lymph nodes. The goal is to see if this approach is safe and effective. The study involves 36 people with early-stage stomach cancer.
Phase: NA • Sponsor: Jilin University • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Supercharged t cells take on Hard-to-Treat cancers
Disease control TEMPORARILY_NOT_AVAILABLEThis treatment program tests a personalized cell therapy for people with advanced pancreatic or colorectal cancers that have a specific genetic mutation (KRAS G12D). Patients' own immune cells are collected, genetically engineered to recognize and attack the cancer, and then infu…
Sponsor: Providence Health & Services • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Major trial pits two drug cocktails against Hard-to-Treat cancers
Disease control OngoingThis study compares two drug combinations for people with advanced neuroendocrine tumors (carcinoid cancer) that cannot be removed by surgery. Participants receive either octreotide plus interferon or octreotide plus bevacizumab. The goal is to see which combination better slows …
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New GERD drug aims to keep esophagus healed, but trial never started
Disease control TerminatedThis study was designed to see if a new drug called linaprazan glurate could keep the esophagus healed in people with GERD-related erosive esophagitis, compared to an existing drug (lansoprazole). Participants would have taken daily pills for up to 52 weeks and had regular camera…
Phase: PHASE3 • Sponsor: Cinclus Pharma Holding AB • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC
-
New targeted drug shows promise for rare genetic cancer
Disease control OngoingThis study tests a new drug called anvumetostat, alone or with chemotherapy (docetaxel), in adults with advanced solid tumors that lack the MTAP gene. The goal is to find the safest dose and see if it shrinks tumors. About 329 people will take part across multiple phases.
Phase: PHASE1, PHASE2 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC
-
New drug runimotamab takes on Hard-to-Treat HER2 cancers
Disease control OngoingThis early-stage trial tests a new drug called runimotamab, alone or with trastuzumab, in 123 people with advanced HER2-positive cancers. The main goal is to check safety and how the drug moves through the body. It is for patients whose cancer has spread or cannot be removed by s…
Phase: PHASE1 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New drug targets Hard-to-Treat cancers in early trial
Disease control OngoingThis study tests an experimental drug called M9140 in people with advanced solid tumors (gastric, lung, or pancreatic cancer) that have a specific protein (CEACAM5). The drug is designed to deliver a toxin directly to cancer cells. About 250 adults will receive the drug alone or …
Phase: PHASE1, PHASE2 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New drug combo takes on Hard-to-Treat cancers in first human test
Disease control OngoingThis early-stage trial is testing an experimental drug called AMG 355, given alone or together with the immunotherapy Keytruda, in 77 adults with advanced solid tumors (like lung, colon, stomach, or melanoma) that have not responded to standard treatments. The main goals are to c…
Phase: PHASE1 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New hope for stomach cancer: targeted drug shows promise in Late-Stage trial
Disease control OngoingThis phase 3 trial compares a newer targeted drug, trastuzumab deruxtecan, against a standard combination of two other drugs (ramucirumab and paclitaxel) in 490 adults with HER2-positive stomach or gastro-esophageal junction cancer that has worsened after initial treatment with t…
Phase: PHASE3 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
MRNA cancer shots: new hope or hype?
Disease control OngoingThis early-stage trial tests two experimental mRNA therapies (mRNA-4106 and mRNA-4200) in 42 people with advanced solid tumors like melanoma, lung, or liver cancer. Some participants receive the mRNA therapy alone, others get it combined with the immunotherapy drug pembrolizumab.…
Phase: PHASE1 • Sponsor: ModernaTX, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New targeted drug shows promise in stomach cancer trial
Disease control OngoingThis Phase 3 trial tests a new drug called AZD0901 against standard chemotherapy in 592 adults with advanced stomach or gastroesophageal junction cancer that has not responded to prior treatments. The drug targets a protein called CLDN18.2 found on some cancer cells. The study me…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New drug aims to shrink GI cancers before surgery
Disease control OngoingThis phase 2 trial tests whether giving the immune checkpoint inhibitor IMC-001 before surgery can shrink tumors in people with resectable gastric, esophageal, or liver cancer. About 48 participants will receive two cycles of the drug, then undergo surgery. The main goal is to se…
Phase: PHASE2 • Sponsor: Asan Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Blood test may help some gastric cancer patients avoid unnecessary chemo
Disease control OngoingThis study explores whether a blood test that detects tiny bits of tumor DNA (ctDNA) can help doctors decide if patients with stage II-III gastric cancer need chemotherapy after surgery. About 65 patients will be followed for three years to see if those with no detectable ctDNA c…
Phase: NA • Sponsor: Qilu Hospital of Shandong University • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New drug IBI343 shows promise in advanced stomach cancer trial
Disease control OngoingThis phase 3 study tests a new drug called IBI343 against standard treatments for people with advanced stomach or gastroesophageal junction cancer that has not responded to prior therapies. The trial includes 464 participants whose tumors have a specific marker (CLDN18.2) and lac…
Phase: PHASE3 • Sponsor: Innovent Biologics (Suzhou) Co. Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New Immune-Cell cocktail takes on tough gut cancers
Disease control OngoingThis phase 2 trial is testing a five-drug combination for people with advanced esophageal, stomach, or gastroesophageal junction cancer that has worsened after initial treatment. The combination includes immune cells from healthy donors, two immunotherapy drugs, and two standard …
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Could surgery after chemo double survival for advanced stomach cancer?
Disease control OngoingThis study looks at whether surgery to remove stomach cancer that has spread to the abdomen can help people live longer when done after chemotherapy. About 300 adults whose cancer responded well to initial treatment will be randomly assigned to either have surgery plus more thera…
Phase: PHASE2, PHASE3 • Sponsor: National University Hospital, Singapore • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New pill targets Hard-to-Treat cancers in early trial
Disease control OngoingThis early-phase study tests a new drug called RMC-6291 in adults with advanced cancers (lung, colon, pancreatic) that have a specific KRAS G12C mutation. The goal is to find the safest dose and see how well the drug works. About 222 participants will receive the drug by mouth, a…
Phase: PHASE1 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New drug cocktail targets Hard-to-Treat tumors
Disease control OngoingThis early-stage trial tests a new oral drug called ceralasertib, given alone or with other cancer treatments like chemotherapy or targeted drugs, in 354 adults with advanced solid tumors that no longer respond to standard care. The main goal is to check safety and find the best …
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New Antibody-Drug conjugate shows promise for Hard-to-Treat cancers
Disease control OngoingThis study tests a new drug called SKB264 in people with advanced solid tumors that have not responded to standard therapies. The drug is an antibody-drug conjugate designed to deliver chemotherapy directly to cancer cells. The trial includes over 1,400 participants with various …
Phase: PHASE1, PHASE2 • Sponsor: Klus Pharma Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New Catheter-Based valve replacement could offer hope for leaky heart valve patients
Disease control OngoingThis study is testing a new device called the Edwards EVOQUE system, which replaces the tricuspid valve using a thin tube (catheter) instead of open-heart surgery. The trial includes 228 people with moderate or severe tricuspid regurgitation who still have symptoms despite medica…
Phase: NA • Sponsor: Edwards Lifesciences • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Battle of the bacteria busters: triple vs quadruple therapy for stomach bug
Disease control ENROLLING_BY_INVITATIONThis study tests two different drug combinations to treat Helicobacter pylori, a stomach bacteria that can cause indigestion. About 66 adults with dyspepsia will receive either a triple therapy (amoxicillin, clarithromycin, esomeprazole) or a quadruple therapy (bismuth, metronida…
Phase: NA • Sponsor: Akil Al Islam • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New stent aims to seal Post-Surgery leaks without another operation
Disease control ENROLLING_BY_INVITATIONThis study tests a new device called the Luso-Cor esophageal stent for closing leaks (fistulas) that can happen after weight-loss or cancer surgery on the stomach or esophagus. About 180 adults will be enrolled and their outcomes compared to those treated with standard stents or …
Sponsor: Unidade Local de Saúde Santa Maria • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New Antibody-Chemo combo shows promise in slowing stomach cancer
Disease control OngoingThis Phase 3 trial tests whether adding zolbetuximab, an antibody that targets the Claudin 18.2 protein found on many stomach tumors, to standard chemotherapy can delay cancer progression in people with advanced stomach or gastroesophageal junction cancer. About 565 adults whose …
Phase: PHASE3 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New chemo combo tested for rare gut cancers – results disappoint
Disease control OngoingThis phase 2 trial tested whether a combination of temozolomide and capecitabine works better than the standard cisplatin and etoposide for people with advanced, hard-to-treat gastrointestinal neuroendocrine carcinomas. The study enrolled 67 participants whose cancer had spread o…
Phase: PHASE2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Smaller incisions, big hopes: new surgery for stomach cancer under trial
Disease control OngoingThis study is testing whether a newer, less invasive type of stomach cancer surgery (using just one or a few small cuts) is as safe and effective as the standard approach. The trial involves 108 people with advanced stomach cancer who need their stomach partially removed. The mai…
Phase: NA • Sponsor: Seoul National University Bundang Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New hope for stomach paralysis? trial combines two procedures
Disease control OngoingThis study tests two procedures—G-POEM and a gastric electrical stimulator—for people with severe gastroparesis (stomach paralysis) that hasn't improved with medication. Forty adults will be randomly assigned to one of two groups to compare safety and symptom relief. The goal is …
Phase: NA • Sponsor: Baylor Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
New antibody drug takes on advanced cancers in first human trial
Disease control OngoingThis early-phase trial is testing a new drug called NTX-1088, which targets a protein on cancer cells, either alone or combined with the immunotherapy pembrolizumab. The study involves 90 people with advanced solid tumors that have spread or cannot be removed. The main goals are …
Phase: PHASE1 • Sponsor: Nectin Therapeutics Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
Could a tiny dose of immunotherapy tame tough cancers?
Disease control ENROLLING_BY_INVITATIONThis study tests a low dose of the immunotherapy drug nivolumab, alone or with chemotherapy, in people with advanced colorectal or stomach cancers that have a specific genetic feature (MSI/dMMR). The goal is to see if this approach can shrink tumors before surgery or control the …
Phase: PHASE2 • Sponsor: Blokhin's Russian Cancer Research Center • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug aims to shrink hard-to-treat GI tumors
Disease control OngoingThis study tests a new medicine called raludotatug deruxtecan in about 160 adults with advanced gastrointestinal cancers (pancreatic, bile duct, gallbladder, colorectal, stomach, or gastroesophageal junction). The drug is designed to attach to cancer cells and deliver a treatment…
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Can nexium keep Kids' esophagitis at bay? new study seeks answers
Disease control OngoingThis phase 3 study tests two doses of Nexium (esomeprazole) in 53 children aged 1 to 11 years who have erosive esophagitis, a condition where stomach acid damages the esophagus. The goal is to see which dose better maintains healing after an initial 8-week treatment period. Child…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Can a 3-Day diet change help stomach cancer patients before surgery?
Disease control ENROLLING_BY_INVITATIONThis early-phase study is testing whether a diet low in the amino acid leucine, given for just three days before surgery, is safe for people with stomach cancer. Researchers will check blood amino acid levels, immune cell changes, and any side effects. The goal is to see if this …
Phase: PHASE1 • Sponsor: Qilu Hospital of Shandong University • Aim: Disease control
Last updated Jun 27, 2026 12:10 UTC
-
New drug cocktail shows promise for tough cancers
Disease control OngoingThis study is testing a combination of three drugs—durvalumab (an immunotherapy), olaparib (a targeted therapy), and bevacizumab (a drug that blocks blood vessel growth)—in people with advanced solid tumors, including ovarian, breast, lung, and gastric cancers. The goal is to see…
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New drug combo shows promise in early stomach cancer trial
Disease control OngoingThis early-phase trial tests a new drug called IDX-1197 combined with standard chemotherapy (XELOX or irinotecan) in 87 people with advanced stomach cancer. The main goal is to find the safest dose and check for side effects. It is not yet known if the combination works better th…
Phase: PHASE1, PHASE2 • Sponsor: Idience Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New drug combo shows promise against tough stomach cancer
Disease control OngoingThis study tests whether adding zolbetuximab (a drug that targets a protein called Claudin 18.2 found on many stomach tumors) to standard chemotherapy helps people with advanced stomach or gastroesophageal junction cancer live longer without their cancer growing. About 500 adults…
Phase: PHASE3 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Can a simple bypass stop reflux after Weight-Loss surgery?
Disease control OngoingThis study looks at whether adding a small bypass (gastroenteroanastomosis) to the standard sleeve gastrectomy can prevent or reduce acid reflux in people with obesity. Sixty patients will be split into two groups: one gets the added bypass, the other does not. Researchers will c…
Phase: NA • Sponsor: Clinica Gastrobese • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New cocktail of drugs and radiation aims to boost stomach cancer treatment before surgery
Disease control OngoingThis pilot study tests whether giving a combination of two immunotherapy drugs (nivolumab and ipilimumab) along with chemotherapy and radiation therapy before surgery can help treat stomach cancer that can be surgically removed. The study includes 32 participants and primarily lo…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New way to deliver chemo for stomach cancer shows promise in early trial
Disease control OngoingThis early-phase trial is testing the safety and best dose of the chemotherapy drug paclitaxel when given directly into the abdomen (intraperitoneal) for people with advanced stomach or gastroesophageal cancer that has spread to the lining of the abdomen. The study involves 27 pa…
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Tiny radiation dose may tame stomach cancer with fewer side effects
Disease control OngoingThis study tests whether a very low dose of radiation (4 Gy) can effectively treat gastric MALT lymphoma, a type of stomach cancer. About 25 adults with stage I to IV disease will receive this ultra low-dose therapy. The goal is to kill tumor cells and shrink tumors while causing…
Phase: EARLY_PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New drug cocktail shows promise against aggressive stomach cancer
Disease control OngoingThis study tests whether adding an immunotherapy drug (atezolizumab) to standard chemotherapy and targeted therapy (trastuzumab) can better shrink HER2-positive stomach or gastroesophageal junction cancer before surgery. About 42 adults with advanced but removable tumors will rec…
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New heart valve replacement offers hope for high-risk patients
Disease control OngoingThis study tests a new device called the Edwards EVOQUE eos mitral valve replacement system. It is for people with a leaky mitral valve who are too high-risk for open-heart surgery. The study will check if the device is safe and works well by looking at complications, heart funct…
Phase: NA • Sponsor: Edwards Lifesciences • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New drug cocktail targets Hard-to-Treat stomach cancer
Disease control OngoingThis phase 2 trial tested a combination of two drugs, berzosertib and irinotecan, in 17 patients with advanced stomach or gastroesophageal junction cancer that has a specific genetic change (TP53 mutation) and was getting worse. The goal was to see if the combination could shrink…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New cocktail of drugs shows promise against stomach cancer in early trial
Disease control OngoingThis phase 2 trial tests whether a combination of lenvatinib, pembrolizumab, and chemotherapy (FLOT) can shrink stomach tumors before surgery and prevent recurrence afterward. It involves 43 adults with untreated, non-metastatic stomach cancer. The main goal is to see how many pa…
Phase: PHASE2 • Sponsor: National Cancer Center Hospital East • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New drug cocktail shows promise in shrinking HER2+ stomach tumors before surgery
Disease control OngoingThis phase 2 study tests two approaches for HER2-positive stomach or gastroesophageal junction cancer that hasn't spread. One group gets trastuzumab deruxtecan alone before surgery. Another group gets a combination of trastuzumab deruxtecan, capecitabine, and durvalumab both befo…
Phase: PHASE2 • Sponsor: National Cancer Center Hospital East • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New combo immunotherapy drug enters human trials for 18 cancers
Disease control OngoingThis early-phase trial tests a new drug called AI-061, which combines two immune-boosting antibodies (anti-PD-1 and anti-CTLA-4) into one treatment. The study will enroll 18 adults with advanced solid tumors that have spread or cannot be removed. The main goals are to find a safe…
Phase: PHASE1 • Sponsor: OncoC4, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Chemo fog targets stomach cancer spread in new trial
Disease control ENROLLING_BY_INVITATIONThis study tests a procedure called PIPAC, which turns chemotherapy drugs into a mist and sprays them directly into the abdomen. It is for people with stomach cancer that has spread to the lining of the belly. The goal is to see if this approach is safe and can help control the d…
Phase: PHASE2 • Sponsor: Chinese University of Hong Kong • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Genetically modified immune cells take on eight cancer types in early trial
Disease control OngoingThis early-stage trial tests a personalized cell therapy called ADP-A2M4CD8 in people with certain cancers that have a specific marker (MAGE-A4). The therapy uses a patient's own immune cells, modified to better attack tumors, and is given alone or with standard immunotherapy dru…
Phase: PHASE1 • Sponsor: USWM CT, LLC • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New cocktail aims to shrink Hard-to-Treat stomach tumors
Disease control OngoingThis phase 2 trial is testing a combination of three drugs—anlotinib, TQB2450, and the SOX chemotherapy regimen—as a first treatment for advanced stomach or gastroesophageal junction cancer that has low PD-L1 expression. The study involves 37 participants and aims to see how well…
Phase: PHASE2 • Sponsor: Yongxu Jia • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New antibody combo takes on Hard-to-Treat stomach cancers
Disease control OngoingThis study tests a new antibody drug, S095029, combined with the immunotherapy pembrolizumab in people with advanced stomach or gastro-esophageal junction cancer that has a specific genetic feature (MSI-H/dMMR). The trial aims to see if the combination is safe and can shrink tumo…
Phase: PHASE1, PHASE2 • Sponsor: Servier Bio-Innovation LLC • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Gene-Guided chemo aims to boost surgery success in stomach cancer
Disease control TerminatedThis pilot trial tests whether using a patient's genetic profile to determine the dose of irinotecan (a chemotherapy drug) can improve outcomes for people with advanced stomach or esophageal cancer. The study combines chemotherapy before and after surgery, with the goal of increa…
Phase: PHASE4 • Sponsor: University of Chicago • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Immunotherapy combo before chemo-radiation shows promise for esophageal cancer
Disease control OngoingThis study tests whether giving immunotherapy drugs (nivolumab alone or with relatlimab) before standard chemoradiation is safe and feasible for people with operable stage II/III esophageal or gastroesophageal junction cancer. About 32 adults will receive the drugs, then chemorad…
Phase: PHASE1 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New hope for Hard-to-Treat cancers?
Disease control OngoingThis early-stage study tests a new drug called DS-1055a in about 40 adults with advanced solid tumors (like head and neck, stomach, or lung cancer) that have come back or spread and no longer respond to standard treatments. The main goal is to check the drug's safety and find the…
Phase: PHASE1 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Jun 27, 2026 11:04 UTC
-
Experimental drug duo targets Hard-to-Treat cancers
Disease control OngoingThis early-phase trial tests two drugs together—sonidegib and pembrolizumab—in 36 adults with advanced solid tumors that have spread. Sonidegib blocks a growth signal in cancer cells, while pembrolizumab helps the immune system attack the tumor. The main goals are to find the saf…
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New hope for stomach cancer: experimental drug combo tested
Disease control OngoingThis phase 2 trial tests whether adding an experimental drug (ONO-4578) to standard immunotherapy (nivolumab) and chemotherapy helps people with advanced HER2-negative stomach cancer. About 226 participants who have not had prior chemotherapy will receive either the experimental …
Phase: PHASE2 • Sponsor: Ono Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New pill aims to keep chemo on track for GI cancer patients
Disease control OngoingThis study tests whether avatrombopag, a pill that boosts platelet production, can help people with gastrointestinal cancer who develop low platelets from chemotherapy. About 60 participants will receive either avatrombopag or a placebo. The goal is to see if the drug can raise p…
Phase: PHASE2 • Sponsor: Hanny Al-Samkari, MD • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Cancer-Killing viruses take on solid tumours in new trial
Disease control OngoingThis phase 1/2 trial tests a vaccine made from two viruses designed to target and kill cancer cells that have a specific protein called MAGE-A3. The viruses are given to 56 people with advanced solid tumours that have not responded to other treatments. The goal is to see if the v…
Phase: PHASE1, PHASE2 • Sponsor: Canadian Cancer Trials Group • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New hope for Post-Surgery sugar crashes: avexitide trial underway
Disease control OngoingThis study tests a drug called avexitide in 75 adults who have dangerous low blood sugar episodes after gastric bypass surgery. Participants receive either the drug or a placebo for 16 weeks to see if it reduces severe sugar crashes. The goal is to control this long-term conditio…
Phase: PHASE3 • Sponsor: Amylyx Pharmaceuticals Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New mRNA vaccine shows promise in fighting solid tumors
Disease control OngoingThis early-stage trial tests an experimental mRNA-based cancer vaccine (mRNA-4157) in 161 people with solid tumors. The vaccine is designed to train the immune system to attack cancer cells. Some participants receive the vaccine alone, while others get it with the immunotherapy d…
Phase: PHASE1 • Sponsor: ModernaTX, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New liposomal drug shows promise for Hard-to-Treat cancers
Disease control OngoingThis early-stage study tests a new drug called E7389 liposomal formulation in people with advanced solid tumors that have not responded to standard treatments. The main goal is to find the safest dose and check for side effects. The study also looks at how the drug works in speci…
Phase: PHASE1 • Sponsor: Eisai Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New hope for stomach cancer: phase 3 trial of MK-2870 launches
Disease control OngoingThis phase 3 trial compares a new drug, MK-2870, against standard treatments for people with advanced stomach, gastroesophageal junction, or esophageal cancer that has spread and not responded to prior therapies. About 450 participants will be randomly assigned to receive either …
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Experimental pill plus keytruda takes on tough cancers
Disease control OngoingThis study tests an experimental oral drug called Q702 combined with the immunotherapy pembrolizumab (Keytruda) in people with advanced esophageal, stomach, liver, or cervical cancer that has worsened after prior treatment. The goal is to see if the combination is safe and can sh…
Phase: PHASE1, PHASE2 • Sponsor: Qurient Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New drug cocktail shows promise for Hard-to-Treat gut cancers
Disease control OngoingThis study is testing a drug called tucatinib combined with other cancer medicines (trastuzumab, chemotherapy, and pembrolizumab) in people with HER2-positive cancers of the digestive system. The main goals are to find safe doses and see what side effects occur. About 40 adults w…
Phase: PHASE2 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New dual-action antibody enters early trials for tough-to-treat cancers
Disease control OngoingThis early-phase study tests an experimental drug called MCLA-129, a bispecific antibody that targets two cancer-related proteins (EGFR and c-MET). It is for people with advanced non-small cell lung cancer, gastric cancer, esophageal cancer, head and neck cancer, or colorectal ca…
Phase: PHASE1, PHASE2 • Sponsor: Merus B.V. • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New drug cocktail aims to shrink Hard-to-Treat cancers
Disease control OngoingThis study tests an experimental drug called AZD5305, a PARP inhibitor, either alone or combined with other cancer drugs in people with advanced solid tumors (like ovarian, breast, pancreatic, and lung cancers). The goal is to see if the treatment is safe and can shrink tumors. A…
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Experimental vaccine aims to boost immune attack on Hard-to-Treat cancers
Disease control OngoingThis study tests a new genetic vaccine called Nous-209, given together with the immunotherapy drug pembrolizumab (Keytruda), in adults with advanced MSI-H or dMMR solid tumors (colorectal, gastric, or gastro-esophageal junction cancers). The vaccine is designed to train the immun…
Phase: PHASE1, PHASE2 • Sponsor: Nouscom SRL • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Donor immune cells take on Hard-to-Treat cancers in early trial
Disease control OngoingThis early-phase trial is testing a new type of cell therapy called P-MUC1C-ALLO1 for people with advanced solid tumors (like breast, ovarian, lung, or pancreatic cancer) that have not responded to other treatments. The therapy uses donor immune cells engineered to recognize and …
Phase: PHASE1 • Sponsor: Poseida Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New No-Scalpel fix for heartburn tested in 500 patients
Disease control ENROLLING_BY_INVITATIONThis study tracks the safety and effectiveness of a procedure called TIF 2.0, which tightens the valve between the stomach and esophagus without any cuts. About 500 adults with acid reflux or throat reflux will be followed to see if their symptoms improve and if they can reduce o…
Sponsor: Cleveland Clinic London • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New combo therapy shows promise for Hard-to-Treat cancers
Disease control OngoingThis study tests a new drug combination (E7389 liposomal formulation plus nivolumab) in 125 people with advanced solid tumors that have not responded to standard treatments. The goal is to find the safest dose and see if the combination can shrink tumors. The study is for people …
Phase: PHASE1, PHASE2 • Sponsor: Eisai Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New hope for advanced stomach cancer: experimental drug LM-302 enters final testing phase
Disease control OngoingThis study tests an experimental drug called LM-302 against standard treatments for people with advanced stomach or gastroesophageal junction cancer that has gotten worse after at least two prior therapies. The trial includes 387 adults whose tumors have a specific protein (CLDN1…
Phase: PHASE3 • Sponsor: LaNova Medicines Zhejiang Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Stomach cancer trial combines Belly-Infused chemo with standard drugs
Disease control OngoingThis phase II trial tests a combination of chemotherapy drugs for stomach cancer that has spread to the lining of the abdomen. About 40 adults will receive standard intravenous chemo plus paclitaxel infused directly into the abdomen. The goal is to see if this approach improves h…
Phase: PHASE2 • Sponsor: University of California, Irvine • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New combo therapy hopes to shrink Hard-to-Treat cancers
Disease control OngoingThis study tests a new drug called HCB101 given together with other cancer treatments for people with advanced solid tumors that have not responded well to prior therapy. About 500 adults will take part to find the safest dose and see if the combination can shrink tumors. The goa…
Phase: PHASE1, PHASE2 • Sponsor: FBD Biologics Limited • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Could 4 months of chemo be enough for stomach cancer?
Disease control OngoingThis study compares 4 months versus 6 months of chemotherapy (capecitabine and oxaliplatin) in 1024 stomach cancer patients who had surgery. The goal is to see if the shorter treatment works just as well to prevent cancer from coming back, while causing fewer side effects. Partic…
Phase: PHASE3 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New combo aims to boost CAR T-Cell success in tough lymphomas
Disease control OngoingThis phase 2 study tests whether adding the drug acalabrutinib to the CAR T-cell therapy lisocabtagene maraleucel (liso-cel) can improve outcomes for people with aggressive B-cell lymphomas that have come back or not responded to treatment. About 28 adults will receive acalabruti…
Phase: PHASE2 • Sponsor: Patrick C. Johnson, MD • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New hope for stomach cancer: targeted combo therapy enters final trial phase
Disease control OngoingThis study tests a new drug called ASKB589 combined with chemotherapy and an immunotherapy for people with advanced stomach or gastroesophageal junction cancer that has spread. The trial includes 780 participants whose tumors have a specific marker (CLDN18.2). The goal is to see …
Phase: PHASE3 • Sponsor: AskGene Pharma, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New drug combo shows promise in shrinking stomach tumors before surgery
Disease control OngoingThis study tests whether adding the drugs camrelizumab and apatinib to standard chemotherapy (SOX) before surgery can help shrink tumors in people with locally advanced stomach or gastroesophageal junction cancer. About 80 participants will receive the treatment before surgery. T…
Phase: PHASE2 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New triple therapy shows promise in stomach cancer fight
Disease control OngoingThis study tests whether adding the immunotherapy drug camrelizumab to standard chemotherapy and the targeted drug apatinib improves outcomes for people with stomach or gastroesophageal junction cancer that can be surgically removed. About 580 adults will receive the treatment be…
Phase: PHASE2, PHASE3 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New cocktail aims to shrink stomach tumors
Disease control ENROLLING_BY_INVITATIONThis early-stage trial tests whether adding two drugs—pucotenlimab (an immunotherapy) and lenvatinib (a targeted therapy)—to standard chemotherapy (SOX) can shrink tumors better than chemotherapy alone in people with advanced HER2-negative stomach or gastroesophageal junction can…
Phase: EARLY_PHASE1 • Sponsor: Fujian Medical University • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Promising stomach cancer combo trial pulled before it even started
Disease control TerminatedThis study aimed to see if adding a targeted drug (bemarituzumab) to standard chemotherapy (FLOT) could improve outcomes for people with a certain type of stomach or gastroesophageal junction cancer that overexpresses FGFR2b. The treatment was given before and after surgery. Howe…
Phase: PHASE2 • Sponsor: Institut Cancerologie de l'Ouest • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Immunotherapy combo shows promise for Hard-to-Treat stomach cancers
Disease control OngoingThis phase II trial is testing whether giving the immunotherapy drug pembrolizumab before standard chemotherapy and radiation can help prevent stomach cancer from coming back. It includes 40 people with operable stomach cancer that has either a specific DNA repair problem (mismat…
Phase: PHASE2 • Sponsor: Rutgers, The State University of New Jersey • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Can a blood injection stop hernias from returning?
Disease control OngoingThis study tests whether injecting platelet-rich plasma (PRP) during hiatal hernia repair can lower the chance of the hernia coming back. About 150 adults with large hiatal hernias will be randomly assigned to get either standard surgery with mesh or surgery plus PRP. The main go…
Phase: NA • Sponsor: University of Southern California • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Experimental cocktail aims to revive immune attack on Hard-to-Treat cancers
Disease control OngoingThis study tests a combination of an experimental immune booster (N-803) with standard checkpoint inhibitors in people with advanced solid tumors (like lung, bladder, or skin cancer) whose disease progressed after prior immunotherapy. The goal is to see if the combo can shrink tu…
Phase: PHASE2 • Sponsor: ImmunityBio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Shorter radiation before stomach cancer surgery shows promise in early trial
Disease control OngoingThis early-phase trial tests whether a shorter course (2 weeks instead of 5) of chemoradiotherapy before standard chemotherapy and surgery is safe and effective for people with resectable stomach cancer. About 25 participants will receive the shortened radiation combined with che…
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New drug trial hopes to shrink Hard-to-Treat tumors
Disease control OngoingThis early-stage study tests a new drug, TORL-2-307-ADC, in 163 people with advanced solid tumors like stomach, pancreas, or esophageal cancer. The goal is to find a safe dose and see if the drug can shrink tumors. Participants must have measurable disease and be well enough for …
Phase: PHASE1 • Sponsor: TORL Biotherapeutics, LLC • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Immunotherapy before surgery shows promise for certain cancers
Disease control OngoingThis study tests whether giving immunotherapy before surgery can help people with MSI/dMMR tumors. The goal is to shrink or eliminate the tumor before it is removed, potentially improving survival. The trial includes adults with localized, resectable cancers such as colorectal, g…
Phase: PHASE2 • Sponsor: Centre Leon Berard • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New antibody shows promise against tough cancers in early trial
Disease control OngoingThis phase 2 study tests a drug called AK104, which helps the immune system attack cancer cells, in people with specific types of stomach or colorectal cancer. Participants receive the drug before and after surgery to see if it can completely eliminate the tumor. The trial involv…
Phase: PHASE2 • Sponsor: Peking University • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Promising combo aims to keep stomach cancer at bay after surgery
Disease control OngoingThis study tests whether adding the immunotherapy drug durvalumab to standard chemotherapy (FLOT) before and after surgery helps people with resectable stomach or gastroesophageal junction cancer live longer without the cancer returning. About 957 participants receive either durv…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Promising cancer combo study pulled before it even started
Disease control TerminatedThis study aimed to see if adding two immune-boosting drugs (zimberelimab and domvanalimab) to standard chemotherapy could help people with operable stomach or esophageal cancer. All participants would have received the treatment before and after surgery, then be followed for up …
Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New antibody combo aims to supercharge immune system against Hard-to-Treat cancers
Disease control OngoingThis early-phase trial is testing an experimental drug called INBRX-106, alone or combined with the immunotherapy Keytruda, in people with advanced solid tumors (including lung, head and neck, melanoma, and others) that have stopped responding to standard treatments. The main goa…
Phase: PHASE1, PHASE2 • Sponsor: Inhibrx Biosciences, Inc • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New targeted combo shows promise for tough stomach cancer
Disease control OngoingThis clinical trial is testing whether adding a targeted drug called bemarituzumab to standard chemotherapy and immunotherapy (nivolumab) helps people with advanced stomach or gastroesophageal junction cancer live longer. The study includes 515 adults whose tumors overexpress a p…
Phase: PHASE3 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New antibody TST001 takes on stomach and pancreatic cancers
Disease control OngoingThis trial tests an experimental drug called TST001, an antibody that targets a protein (Claudin 18.2) found on some cancer cells. It is being studied alone or combined with other treatments like nivolumab or chemotherapy in 150 people with advanced stomach, gastroesophageal junc…
Phase: PHASE1, PHASE2 • Sponsor: Suzhou Transcenta Therapeutics Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
Engineered immune cells take on Hard-to-Treat cancers in early trial
Disease control OngoingThis early-phase trial is testing a new treatment called LB1908, which uses a patient's own immune cells (T-cells) that have been modified in the lab to recognize and attack cancer cells that have a protein called claudin 18.2 on their surface. The study includes up to 56 adults …
Phase: PHASE1 • Sponsor: Legend Biotech USA Inc • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New hope for stomach cancer: targeted drug combo enters human trials
Disease control OngoingThis study tests a new drug called bemarituzumab, given together with chemotherapy and an immunotherapy drug (nivolumab), in 72 adults with advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery. The main goals are to check safety and see if the co…
Phase: PHASE1, PHASE2 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
Immunotherapy plus chemo shows promise against tough stomach cancer
Disease control OngoingThis phase 2 trial tests whether adding the immunotherapy drug serplulimab to standard FLOT chemotherapy can improve outcomes for people with stage III gastric cancer. About 138 participants will receive either the combo or chemo alone before surgery. The main goal is to see if t…
Phase: PHASE2 • Sponsor: Guangdong Provincial People's Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Endoscopic obesity treatments under 10-Year microscope
Disease control ENROLLING_BY_INVITATIONThis study will follow 5,000 adults who have had endoscopic procedures for weight loss, such as stomach stapling through a scope or gastric balloons. Researchers will track weight, blood pressure, diabetes, and cholesterol for up to 10 years to see how well these procedures work …
Sponsor: Christopher C. Thompson, MD, MSc • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Triple drug cocktail targets tough stomach cancer
Disease control OngoingThis phase 2 study is testing a combination of three drugs—paclitaxel (a chemotherapy), pembrolizumab (an immunotherapy), and olaparib (a targeted therapy)—in 36 adults with advanced gastric or gastroesophageal cancer that has worsened after one prior treatment. The goal is to se…
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New drug duo hopes to boost immune system against tough cancers
Disease control OngoingThis early-stage trial is testing a new drug called HFB200301, either alone or with another drug (tislelizumab), in 72 adults with advanced solid tumors like lung, stomach, or skin cancer. The main goal is to check safety and find the best dose. Researchers will also watch for an…
Phase: PHASE1 • Sponsor: HiFiBiO Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New drug cocktail targets Hard-to-Treat HER2 cancers
Disease control OngoingThis early-stage trial is testing a new drug called ELVN-002 in combination with trastuzumab and chemotherapy for people with advanced HER2-positive solid tumors, including breast, gastric, and colorectal cancers. The main goal is to find a safe dose and understand side effects. …
Phase: PHASE1 • Sponsor: Enliven Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New drug BT5528 targets Hard-to-Treat cancers in early trial
Disease control OngoingThis study tests an experimental drug called BT5528, given alone or with another drug (nivolumab), in people with advanced solid tumors that have high levels of a protein called EphA2. The cancers include ovarian, bladder, lung, breast, head and neck, and stomach cancers. The mai…
Phase: PHASE1, PHASE2 • Sponsor: BicycleTx Limited • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New drug shows promise against tough cancers
Disease control OngoingThis study tests a drug called sacituzumab govitecan in 53 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to see if the drug can shrink tumors. Researchers will also track how long any response lasts and how well the drug contro…
Phase: PHASE2 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New drug BT8009 targets Hard-to-Treat cancers in early trial
Disease control OngoingThis study tests a new drug called BT8009, alone or with another drug (pembrolizumab), in people with advanced solid tumors like bladder, breast, lung, or ovarian cancer. The drug targets a protein called Nectin-4 found on some cancer cells. The trial aims to find safe doses and …
Phase: PHASE1, PHASE2 • Sponsor: BicycleTx Limited • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Donor immune cells get a boost in new cancer trial
Disease control TerminatedThis early-phase study tests whether giving healthy donor NK cells along with two medicines (vactosertib and IL-2) is safe and helps the cells stay active in people with advanced colorectal, stomach, esophageal, or blood cancers. The NK cells are meant to attack cancer, but the b…
Phase: PHASE1 • Sponsor: David Wald • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New drug BL-M17D1 targets Hard-to-Treat HER2 cancers in early trial
Disease control OngoingThis early-stage study tests a new drug called BL-M17D1 in 120 adults with advanced solid tumors that have HER2 protein or gene changes. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. Participants must have tried at least one standard…
Phase: PHASE1 • Sponsor: SystImmune Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New combo therapy offers hope for hard-to-treat GI cancers
Disease control OngoingThis study tests a combination of two drugs (vorbipiprant and balstilimab) in people with advanced colorectal or other gastrointestinal cancers that have not responded to prior treatments. The goal is to see if the combination is safe and can shrink tumors or slow disease progres…
Phase: PHASE1, PHASE2 • Sponsor: Rottapharm Biotech • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New antibody drug takes on tough cancers
Disease control OngoingThis study tests an experimental drug called AZD7789 in people with advanced lung, stomach, or gastroesophageal cancer that cannot be removed by surgery. The drug is a bispecific antibody designed to help the immune system attack cancer cells. The trial aims to check if the drug …
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Promising cocktail may turn inoperable stomach cancer into surgical candidates
Disease control OngoingThis phase II trial tests a combination of three drugs—fruquintinib, sintilimab, and SOX (S-1 plus oxaliplatin)—as a pre-surgery treatment for people with stage IV gastric cancer that cannot be fully removed. The goal is to shrink the tumor enough to allow complete surgical remov…
Phase: PHASE2 • Sponsor: Henan Cancer Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
New drug targets Hard-to-Treat cancers with MET mutations
Disease control OngoingThis early-stage trial tests a new drug called TPX-0022 in adults with advanced lung, stomach, or other solid tumors that have specific MET gene changes. The main goals are to check the drug's safety, find the best dose, and see if it shrinks tumors. About 95 participants will ta…
Phase: PHASE1 • Sponsor: Turning Point Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New hope for stomach cancer: drug combo targets tumors
Disease control OngoingThis study tests a new drug (RC48-ADC) combined with immunotherapy (toripalimab) and either chemotherapy or another targeted drug (trastuzumab) as a first treatment for people with advanced stomach cancer. About 201 adults aged 18-75 with HER2-positive or HER2-negative stomach ca…
Phase: PHASE2, PHASE3 • Sponsor: RemeGen Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New Dual-Action antibody takes on advanced cancers
Disease control OngoingThis early-phase study tests a new drug called SI-B003 in 60 people with advanced solid tumors that have spread or come back. The drug is a bispecific antibody designed to help the immune system attack cancer cells. The main goals are to find a safe dose and check for side effect…
Phase: PHASE1 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New hope for Post-Surgery sugar crashes: pasireotide under study
Disease control OngoingThis phase 2 trial tests the drug pasireotide in 93 adults who experience severe low blood sugar after weight-loss surgery. Participants receive either the drug or a placebo for 12 weeks, then all can receive the drug for 36 more weeks. The goal is to see if pasireotide can stabi…
Phase: PHASE2 • Sponsor: RECORDATI GROUP • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New hope for heartburn sufferers: study tests combo therapy for NERD
Disease control OngoingThis study is testing a new combination treatment for non-erosive reflux disease (NERD), a common form of GERD that causes heartburn and other symptoms. The treatment adds therapies to strengthen the esophagus's natural barrier on top of standard acid-reducing medication. Researc…
Sponsor: I.M. Sechenov First Moscow State Medical University • Aim: Disease control
Last updated Jun 26, 2026 18:27 UTC
-
Band-Aid for heartburn? new endoscopic fix could cut reflux meds
Disease control ENROLLING_BY_INVITATIONThis small study tests an endoscopic procedure that uses band ligation to tighten the lower esophagus and upper stomach, aiming to reduce acid reflux in people who had gastric sleeve surgery. Twelve participants will undergo the procedure and be monitored for six months to see if…
Phase: NA • Sponsor: St. Olavs Hospital • Aim: Disease control
Last updated Jun 26, 2026 17:33 UTC
-
Triple-Drug chemo blitz aims to boost stomach cancer survival
Disease control OngoingThis phase 2 trial tests whether adding a third chemotherapy drug (irinotecan) to the standard two-drug regimen (FOLFOX) improves outcomes for patients with resectable stomach or gastroesophageal junction cancer. 60 participants receive the three-drug combo before and after surge…
Phase: PHASE2 • Sponsor: Lund University Hospital • Aim: Disease control
Last updated Jun 26, 2026 16:23 UTC
-
Tiny implant could stop heartburn without pills
Disease control OngoingThis early study tests a small, permanent device called the Omega-Cuff in 8 adults with GERD. Placed around the weak esophageal sphincter during keyhole surgery, it aims to block acid from backing up while allowing food to pass normally. Researchers will check safety, acid levels…
Phase: NA • Sponsor: Aplos Medical • Aim: Disease control
Last updated Jun 26, 2026 16:15 UTC
-
New cocktail targets Hard-to-Treat stomach cancer
Disease control OngoingThis early-stage trial is testing a new drug called ASKB589, which targets a protein (CLDN18.2) found on some stomach cancer cells. It is given together with standard chemotherapy and an immunotherapy drug. The study includes 62 people with advanced stomach or gastroesophageal ju…
Phase: PHASE1, PHASE2 • Sponsor: AskGene Pharma, Inc. • Aim: Disease control
Last updated Jun 26, 2026 16:04 UTC
-
New drug ASKB589 tested against advanced cancers
Disease control OngoingThis study tests an experimental drug called ASKB589 in about 199 people with advanced solid tumors that have spread. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. People with stomach or pancreatic cancer are especially wanted for …
Phase: PHASE1, PHASE2 • Sponsor: Jiangsu Aosaikang Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 26, 2026 15:35 UTC
-
New immunotherapy cocktail targets Hard-to-Treat cancers
Disease control OngoingThis Phase 2 trial tests whether adding an experimental immunotherapy drug (SHR-8068) to a standard immunotherapy (adebrelimab) plus chemotherapy can shrink tumors better than standard treatment alone in people with advanced stomach or esophageal cancer. About 153 participants wi…
Phase: PHASE2 • Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 26, 2026 13:05 UTC
-
New PET tracer could spot cancers that standard scans overlook
Diagnosis OngoingThis phase 1 trial is testing a new imaging tracer called 68Ga-FAPI-46 to see where it collects in normal and cancerous tissues. About 30 people with various solid tumors or blood cancers will receive the tracer and then undergo a PET/CT scan. The goal is to understand how the tr…
Phase: PHASE1 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Diagnosis
Last updated Jul 04, 2026 00:00 UTC
-
New device could make GERD diagnosis quicker and less painful
Diagnosis ENROLLING_BY_INVITATIONThis study is testing a new, less invasive device that measures the health of the esophagus in people with acid reflux (GERD). Researchers will compare two versions of the device in 75 patients undergoing routine endoscopy. The goal is to see if this technology can diagnose GERD …
Sponsor: Vanderbilt University Medical Center • Aim: Diagnosis
Last updated Jun 28, 2026 00:00 UTC
-
New CT technique could spot stomach cancer spread without surgery
Diagnosis OngoingThis study looks at whether a special type of CT scan (spectral CT) combined with a tumor marker (MSI status) can more accurately predict if stomach cancer has spread to nearby lymph nodes. Researchers will compare the CT results with the actual lymph node findings after surgery …
Phase: NA • Sponsor: Yunnan Cancer Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 12:28 UTC
-
Stomach 'EKG' could spot hidden gut problems
Diagnosis ENROLLING_BY_INVITATIONThis study is testing a new device called Gastric Alimetry that records the stomach's electrical activity through electrodes placed on the belly. Researchers want to see if it can reliably detect abnormal stomach rhythms in people with conditions like gastroparesis and functional…
Sponsor: University of Calgary • Aim: Diagnosis
Last updated Jun 27, 2026 12:23 UTC
-
Magnetic map may improve cancer staging
Diagnosis OngoingThis study tests a new magnetic tracer, FerroTrace, to find sentinel lymph nodes in people with stomach or esophageal cancer. About 60 participants will receive the tracer before standard treatment, and doctors will compare its accuracy to current methods. The goal is to see if t…
Phase: NA • Sponsor: Ferronova Pty Ltd • Aim: Diagnosis
Last updated Jun 27, 2026 12:04 UTC
-
New heartburn test could replace uncomfortable procedures
Diagnosis ENROLLING_BY_INVITATIONThis study tests whether a 4-week course of vonoprazan, a stronger acid blocker, can help identify which patients with persistent heartburn actually have acid reflux. About 100 adults with symptoms that don't improve on standard treatment will take the drug and complete symptom q…
Phase: NA • Sponsor: Fu Jen Catholic University Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 09:08 UTC
-
AI eye in the scope: new tool aims to catch stomach cancer earlier
Diagnosis OngoingThis study tests whether an artificial intelligence system (called CADe) can help doctors spot early stomach cancers during endoscopy. About 260 people at high risk for stomach cancer will have two endoscopies: one without the AI and one with it. The goal is to see if the AI redu…
Phase: NA • Sponsor: Chinese University of Hong Kong • Aim: Diagnosis
Last updated Jun 27, 2026 09:03 UTC
-
Stool test could spot stomach cancer before it spreads
Diagnosis OngoingThis study looks at whether testing stool (feces) for certain DNA changes and bacteria genes can help find stomach cancer early. Researchers will follow 3000 people, including those with and without cancer, to see how well the test works. The goal is to improve early diagnosis an…
Sponsor: Fudan University • Aim: Diagnosis
Last updated Jun 27, 2026 08:07 UTC
-
Heated chemo during surgery may stop stomach Cancer's return
Prevention ENROLLING_BY_INVITATIONThis study tests whether giving heated chemotherapy directly into the abdomen during surgery can prevent stomach or gastroesophageal junction cancer from returning in the abdominal lining. The treatment uses drugs cisplatin and paclitaxel, which are heated and circulated in the b…
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Prevention
Last updated Jul 03, 2026 00:00 UTC
-
Turmeric compound tested to stop stomach cancer before it starts
Prevention OngoingThis study tests whether curcumin, a compound found in turmeric, can prevent stomach cancer in people with chronic atrophic gastritis or gastric intestinal metaplasia. About 50 participants will receive either curcumin or a placebo for a period, and researchers will measure chang…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Prevention
Last updated Jun 27, 2026 12:23 UTC
-
Free stomach infection test and treatment could prevent cancer in at-risk communities
Prevention OngoingThis study screens 500 adults in South Florida for H. pylori, a stomach infection that can lead to chronic gastritis, ulcers, and gastric cancer. Those who test positive receive free treatment with a three-drug combination (VOQUEZNA® Triple Pak®) for 14 days. The goal is to see i…
Phase: PHASE4 • Sponsor: University of Miami • Aim: Prevention
Last updated Jun 27, 2026 09:06 UTC
-
At-Home breath test could help prevent stomach cancer
Prevention OngoingThis study screens people in South Florida for H. pylori, a stomach infection that can lead to chronic gastritis, ulcers, and even stomach cancer. Those who test positive receive treatment, and the study compares at-home breath testing versus in-person retesting to confirm the in…
Phase: PHASE4 • Sponsor: University of Miami • Aim: Prevention
Last updated Jun 27, 2026 09:05 UTC
-
New feeding technique may protect tiny lungs in preterm babies
Prevention OngoingThis study looks at whether feeding preterm babies (weighing less than 3.3 pounds) through a tube placed past the stomach can prevent small amounts of stomach fluid from getting into their lungs. The goal is to reduce lung inflammation. About 46 babies on breathing machines will …
Sponsor: Nemours Children's Clinic • Aim: Prevention
Last updated Jun 27, 2026 08:06 UTC
-
40,000-Person study aims to stop two cancers before they start
Prevention ENROLLING_BY_INVITATIONThis study tests whether personalized screening can prevent stomach and colon cancer in 40,000 healthy adults aged 50-75. For stomach cancer, researchers combine a test for H. pylori bacteria with a blood test for stomach damage to identify high-risk individuals. For colon cancer…
Sponsor: National Taiwan University Hospital • Aim: Prevention
Last updated Jun 27, 2026 08:05 UTC
-
Home monitoring may keep cancer patients out of the ER
Symptom relief OngoingThis study tests whether using telemedicine and remote monitoring can help people with advanced digestive cancers manage chemotherapy side effects at home, reducing the need for emergency room visits and hospital stays. About 750 patients and their caregivers will receive enhance…
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
Speech therapy may prevent unnecessary surgery for GERD belching
Symptom relief ENROLLING_BY_INVITATIONThis study looks at whether speech therapy can reduce air-related symptoms like belching and bloating in people with GERD. Researchers will compare symptoms before and after therapy in 100 adults. The goal is to see if speech therapy can help patients avoid antireflux surgery, wh…
Sponsor: Prof Urs Zingg • Aim: Symptom relief
Last updated Jun 27, 2026 13:08 UTC
-
Magnetic zaps to the spine could ease diabetic stomach troubles
Symptom relief OngoingThis early-stage trial tests a noninvasive device that uses magnetic pulses to stimulate nerves in the upper back. The goal is to reduce severe nausea, vomiting, and stomach pain in people with diabetic gastroparesis (stomach paralysis). About 48 adults with moderate-to-severe sy…
Phase: PHASE1 • Sponsor: Medical University of South Carolina • Aim: Symptom relief
Last updated Jun 27, 2026 13:07 UTC
-
Spinal vs. IV pain drugs: which works best for reflux surgery?
Symptom relief ENROLLING_BY_INVITATIONThis study looks at three ways to manage pain during and after laparoscopic Nissen fundoplication (a surgery for acid reflux). About 63 adults will receive either a spinal injection of morphine, a spinal injection of fentanyl, or morphine through an IV. Researchers will measure t…
Phase: NA • Sponsor: Karlstad Central Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 13:02 UTC
-
New stent aims to help cancer patients eat again without surgery
Symptom relief TerminatedThis study tests a special stent placed using an endoscope to connect the stomach to the small intestine in people whose stomach is blocked by advanced cancer. The goal is to help them eat and drink more easily without major surgery. The study plans to enroll 67 participants and …
Phase: NA • Sponsor: Boston Scientific Corporation • Aim: Symptom relief
Last updated Jun 27, 2026 13:00 UTC
-
New hope for kids with heartburn: study tests daily pill
Symptom relief OngoingThis study tests whether a daily medicine called dexlansoprazole can safely reduce symptoms of gastroesophageal reflux disease (GERD) in children aged 2 to 11 years who have heartburn but no damage to their esophagus. About 71 children will take the medicine or a placebo for 12 w…
Phase: PHASE2 • Sponsor: Takeda • Aim: Symptom relief
Last updated Jun 27, 2026 12:35 UTC
-
New injection could spare cancer patients from repeated belly drains
Symptom relief OngoingThis Phase 3 trial tests a drug called M701, given as an injection into the belly, to see if it can reduce the need for draining fluid in people with malignant ascites from advanced stomach, colorectal, or ovarian cancer. About 312 participants will either receive M701 plus drain…
Phase: PHASE3 • Sponsor: Wuhan YZY Biopharma Co., Ltd. • Aim: Symptom relief
Last updated Jun 27, 2026 12:32 UTC
-
New drug hopes to boost Radiation's punch against tough gut cancers
Symptom relief OngoingThis early-phase study tests an oral drug called ropidoxuridine (IPdR) in people with advanced gastrointestinal cancers that cannot be cured. The goal is to find the safest dose and see if it can make radiation therapy more effective at shrinking tumors. Nineteen participants wit…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Symptom relief
Last updated Jun 27, 2026 12:06 UTC
-
Which painkiller wins after hernia surgery? new trial tests BDE vs exparel
Symptom relief ENROLLING_BY_INVITATIONThis phase 2 trial compares two numbing medications—BDE (a mix of bupivacaine, dexamethasone, and epinephrine) and Exparel—to see which one reduces pain better after hernia surgery. About 128 adults having abdominal wall reconstruction will receive one of the drugs during a nerve…
Phase: PHASE2 • Sponsor: Baylor Research Institute • Aim: Symptom relief
Last updated Jun 27, 2026 12:05 UTC
-
Ear device may calm stomach pain without drugs
Symptom relief OngoingThis study tests whether a small device worn behind the ear, which sends mild electrical pulses to nerves, can reduce abdominal pain in adults with gastroparesis-like symptoms (slow stomach emptying). About 140 participants will be randomly assigned to receive either the active d…
Phase: NA • Sponsor: The Cleveland Clinic • Aim: Symptom relief
Last updated Jun 27, 2026 12:00 UTC
-
Could a prebiotic syrup help tame stubborn heartburn?
Symptom relief OngoingThis Phase 2 trial tests whether a prebiotic syrup called MHS-1031 (PIMO) can increase heartburn-free days when added to standard proton pump inhibitor (PPI) therapy for people with GERD. About 247 adults who still have heartburn despite taking PPIs will receive either the syrup …
Phase: PHASE2 • Sponsor: Microbiome Health Sciences • Aim: Symptom relief
Last updated Jun 27, 2026 12:00 UTC
-
Can a simple assessment make chemotherapy safer for seniors?
Symptom relief OngoingThis study tests whether a personalized care plan, based on a geriatric assessment, can reduce severe side effects in older adults (65+) starting chemotherapy for common cancers. Participants are randomly assigned to receive the assessment-driven plan plus usual care, or usual ca…
Phase: NA • Sponsor: The University of Hong Kong • Aim: Symptom relief
Last updated Jun 27, 2026 11:03 UTC
-
New hope for kids with chronic upset stomach: drug trial shows promise
Symptom relief OngoingThis study tests a medicine called Z-338 in children aged 9 to 17 who have functional dyspepsia, a condition causing stomach pain and fullness after eating. The trial has two parts: first checking how the drug moves through the body, then comparing it to a placebo over 28 days to…
Phase: PHASE3 • Sponsor: Zeria Pharmaceutical • Aim: Symptom relief
Last updated Jun 27, 2026 11:03 UTC
-
VR headsets tested as new treatment for stomach paralysis
Symptom relief TerminatedThis pilot study from Mayo Clinic tests whether using a virtual reality headset can safely ease symptoms of gastroparesis, a condition where the stomach empties too slowly. Thirty adults with gastroparesis will try VR programs with games, meditation, and relaxation exercises. The…
Phase: NA • Sponsor: Mayo Clinic • Aim: Symptom relief
Last updated Jun 27, 2026 09:11 UTC
-
Can a simple Post-Surgery plan boost recovery for stomach cancer patients?
Symptom relief ENROLLING_BY_INVITATIONThis study looks at whether a structured care plan right after surgery can improve quality of life and recovery for people with gastric cancer who had chemotherapy or radiation before surgery. About 264 adults aged 18-80 will take part. The goal is to see if this approach reduces…
Phase: NA • Sponsor: Qilu Hospital of Shandong University • Aim: Symptom relief
Last updated Jun 27, 2026 09:09 UTC
-
Which surgery best unblocks stomach cancer? new trial aims to find out
Symptom relief OngoingThis trial compares two surgeries—removing part of the stomach (resection) versus creating a bypass—to relieve blockages in advanced stomach cancer. It includes 63 patients with obstructed tumors. The main goal is to see which procedure better eases symptoms like nausea and vomit…
Phase: NA • Sponsor: Zagazig University • Aim: Symptom relief
Last updated Jun 27, 2026 09:09 UTC
-
New pill aims to calm stomach paralysis nausea
Symptom relief OngoingThis Phase 2 trial tests whether CIN-102 (deudomperidone) can reduce nausea in adults with idiopathic gastroparesis, a condition where the stomach empties slowly. Over 400 participants will take either 10 mg, 15 mg, or a placebo twice daily for 12 weeks. Researchers will track sy…
Phase: PHASE2 • Sponsor: CinDome Pharma, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 09:08 UTC
-
New recovery protocol aims to get stomach cancer patients home sooner
Symptom relief OngoingThis phase II trial tests an enhanced recovery after surgery (ERAS) protocol in 52 people with stage 0 to IIIC gastric cancer who are having surgery. The goal is to see if this approach can reduce pain, nausea, and hospital stays while improving quality of life. Participants rece…
Sponsor: City of Hope Medical Center • Aim: Symptom relief
Last updated Jun 27, 2026 09:07 UTC
-
Music before surgery may cut painkiller use
Symptom relief ENROLLING_BY_INVITATIONThis study looks at whether playing music before or during hernia repair surgery can help lower pain after the operation. About 308 adults having surgery at Bethesda Surgery Center will take part. Researchers will measure pain scores and how much narcotic pain medicine is needed …
Phase: NA • Sponsor: TriHealth Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 09:06 UTC
-
Painkiller-Sparing nerve block trial pulled before it began
Symptom relief TerminatedThis study planned to test a laparoscopic-guided nerve block (TAP block) to reduce opioid painkiller use after weight-loss or anti-reflux stomach surgeries. It compared two numbing medicines, Bupivacaine HCL and Exparel. However, the trial was withdrawn before enrolling any parti…
Phase: PHASE2, PHASE3 • Sponsor: Baylor Research Institute • Aim: Symptom relief
Last updated Jun 27, 2026 09:04 UTC
-
Could early palliative care before cancer surgery improve quality of life?
Symptom relief OngoingThis study looks at whether adding a palliative care team early, before surgery, helps cancer patients manage symptoms like pain, fatigue, and anxiety. About 236 adults having certain abdominal cancer surgeries will either get usual care or usual care plus palliative support. The…
Phase: NA • Sponsor: Vanderbilt University Medical Center • Aim: Symptom relief
Last updated Jun 27, 2026 09:00 UTC
-
New procedure offers hope for stomach paralysis sufferers
Symptom relief OngoingThis study tests a procedure called per-oral pyloromyotomy (POP) to see if it helps people with gastroparesis, a condition where the stomach empties too slowly. About 100 adults who have not improved with standard treatment will be randomly assigned to either the real procedure o…
Phase: NA • Sponsor: Matthew Allemang • Aim: Symptom relief
Last updated Jun 27, 2026 08:14 UTC
-
Desperate patients get access to unapproved drug for stomach paralysis
Symptom relief NO_LONGER_AVAILABLEThis program allows people aged 12 and older with severe stomach or gut problems, like gastroparesis, to try domperidone when standard treatments have failed. The goal is to ease symptoms such as nausea, vomiting, and severe indigestion. The drug is not FDA-approved but is availa…
Sponsor: Wake Forest University Health Sciences • Aim: Symptom relief
Last updated Jun 27, 2026 08:13 UTC
-
Could this pill ease chronic stomach pain?
Symptom relief ENROLLING_BY_INVITATIONThis study tests a drug called tradipitant for people with functional dyspepsia, a condition causing stomach pain and fullness after eating. Researchers will compare the drug to a placebo in 60 adults to see if it improves stomach function and reduces symptoms. The goal is to fin…
Phase: PHASE2 • Sponsor: Xiao Jing (Iris) Wang • Aim: Symptom relief
Last updated Jun 27, 2026 08:12 UTC
-
Diet over pills: new study tests food as reflux remedy
Symptom relief OngoingThis study tests whether the Gracie Diet can reduce symptoms of gastroesophageal reflux disease (GERD) in adults who want to stop taking standard acid-reducing drugs. About 30 participants will stop their medication and follow the diet for 8 weeks. Researchers will track symptom …
Phase: NA • Sponsor: Johns Hopkins University • Aim: Symptom relief
Last updated Jun 27, 2026 08:11 UTC
-
Virtual diet coaching aims to boost nutrition after stomach cancer surgery
Symptom relief OngoingThis study tests a telehealth program designed to help people improve their diet and quality of life after surgery for stomach or esophagus cancer. About 53 patients who have had curative surgery will receive virtual sessions with diet support. The goal is to see if the program i…
Phase: NA • Sponsor: City of Hope Medical Center • Aim: Symptom relief
Last updated Jun 27, 2026 08:09 UTC
-
New pouch surgery aims to ease dumping syndrome after stomach removal
Symptom relief OngoingThis study tests a surgical technique called a jejunal pouch in 26 adults who need their entire stomach removed due to cancer or a high-risk gene mutation. The pouch is created from a section of the small intestine to replace the stomach's reservoir function. The goal is to reduc…
Phase: NA • Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Symptom relief
Last updated Jun 27, 2026 08:08 UTC
-
New study aims to find best way to unblock stomachs in cancer patients
Symptom relief ENROLLING_BY_INVITATIONThis study compares two endoscopic procedures—EUS-guided gastroenterostomy and metal stent placement—for relieving stomach blockage caused by cancer. Researchers will track 200 patients to see which procedure works better, focusing on how long relief lasts, ability to eat, and qu…
Sponsor: National Taiwan University Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 08:04 UTC
-
FitBit and app aim to keep cancer surgery patients out of the hospital
Symptom relief OngoingThis study tests whether using a FitBit and a mobile app can help people recover at home after surgery for stomach, liver, colon, or other GI cancers. About 107 patients will either use the devices plus standard care, or standard care alone. The app tracks activity and symptoms, …
Phase: NA • Sponsor: Weill Medical College of Cornell University • Aim: Symptom relief
Last updated Jun 27, 2026 08:04 UTC
-
Which ablation method do patients prefer for throat patches?
Symptom relief OngoingThis study looks at two ways to remove small throat patches (inlet patches) that can cause discomfort in people with GERD. About 72 participants will receive either argon plasma or radiofrequency ablation. The goal is to see which method patients find more comfortable and which w…
Phase: NA • Sponsor: Assaf-Harofeh Medical Center • Aim: Symptom relief
Last updated Jun 27, 2026 08:02 UTC
-
New study aims to find the best Weight-Loss surgery for fewer side effects
Symptom relief OngoingThis study compares two types of weight-loss surgery—sleeve gastrectomy alone versus sleeve gastrectomy with transit bipartition—to see which leads to fewer cases of dumping syndrome (nausea, diarrhea, dizziness after eating) and better quality of life. Researchers will follow 20…
Phase: NA • Sponsor: Mina Kamal Gergis Erian • Aim: Symptom relief
Last updated Jun 27, 2026 08:01 UTC
-
Which radiation schedule tames spreading cancer best? new study aims to find out
Symptom relief OngoingThis study compares two ways of giving high-dose radiation to people whose cancer has spread to bones, spine, soft tissue, or lymph nodes. One schedule gives the radiation in one day, the other over three days. The goal is to see which schedule better controls tumor growth and ha…
Phase: PHASE3 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 07:56 UTC
-
Green dye could help surgeons prevent stomach ulcers after bypass
Symptom relief OngoingThis study tests whether a safe green dye, injected during gastric bypass surgery, can help surgeons see blood flow to the new stomach connection. Poor blood flow can lead to ulcers, leaks, or narrowing. The trial involves 300 adults and will follow them for two years to see if u…
Phase: PHASE4 • Sponsor: University Health Network, Toronto • Aim: Symptom relief
Last updated Jun 27, 2026 07:54 UTC
-
Cancer treatment gets personal: MATCH trial tests Gene-Guided drugs
Knowledge-focused OngoingThis phase II trial, called MATCH, is testing whether treating cancer based on the genetic makeup of a patient's tumor works better than standard treatments. Over 6,400 adults with advanced solid tumors, lymphomas, or multiple myeloma that have not responded to prior therapy are …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
AI-Guided radiation may shield ovaries in young cancer patients
Knowledge-focused OngoingThis study tests whether a new type of adaptive radiotherapy can reduce radiation exposure to the ovaries in young women (ages 18-50) receiving pelvic radiation for cancers like uterine, rectal, or cervical cancer. Using advanced imaging and an AI treatment planning system, resea…
Sponsor: Washington University School of Medicine • Aim: Knowledge-focused
Last updated Jul 03, 2026 00:00 UTC
-
Real-World study tracks Nivolumab's impact on advanced stomach and esophageal cancers
Knowledge-focused OngoingThis study looks at how the immunotherapy drug nivolumab is used in routine care for adults with advanced cancers of the esophagus, gastroesophageal junction, or stomach. Researchers will analyze data from a Dutch cancer registry to see how long people live after starting nivolum…
Sponsor: Bristol-Myers Squibb • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Surgery insight: how hernia repair affects the stomach valve
Knowledge-focused OngoingThis study looks at how hiatal hernia repair surgery changes the flexibility of the junction between the esophagus and stomach. Researchers will use a special balloon device during surgery to measure this flexibility in 25 adults. They hope to find links between these measurement…
Phase: NA • Sponsor: Wake Forest University Health Sciences • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Can a simple DNA test predict esophageal cancer before it starts?
Knowledge-focused OngoingThis study aims to find early DNA changes in blood and esophageal tissue that could signal a higher risk of developing esophageal cancer. Researchers are studying 600 people with gastroesophageal reflux, Barrett's esophagus, or esophageal cancer who are already scheduled for an u…
Sponsor: Johns Hopkins University • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Silent reflux risk after Weight-Loss surgery revealed
Knowledge-focused OngoingThis study follows 250 obese adults who are having a weight-loss procedure—either surgery or an endoscopic stomach reduction. The goal is to see how often acid reflux (GERD) develops afterward, including silent reflux with no symptoms. By tracking symptoms and using tests, resear…
Sponsor: Johns Hopkins University • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Gut bacteria mystery: 200 patients to help uncover hidden cause of stomach pain
Knowledge-focused ENROLLING_BY_INVITATIONThis study looks at 200 people with ongoing stomach discomfort (functional dyspepsia) to find out how often they have small intestinal bacterial overgrowth (SIBO). Researchers will compare two methods—growing bacteria in a lab and DNA testing—to identify which germs are present. …
Sponsor: Indiana University • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
New MRI technique could shed light on stomach disorder
Knowledge-focused OngoingThis study uses MRI scans to look at the brain and upper digestive tract in people with gastroparesis and healthy volunteers. The goal is to better understand how the brain and gut interact in this condition. Researchers will compare stomach movements before and after meals. This…
Phase: NA • Sponsor: Indiana University • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Tracking a promising therapy for stomach paralysis
Knowledge-focused ENROLLING_BY_INVITATIONThis study creates a registry of people with gastroparesis—a condition where the stomach empties too slowly, causing nausea, vomiting, and pain—who have received a gastric electrical stimulation (GES) device. The goal is to collect long-term data to help researchers understand ho…
Sponsor: Indiana University • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Gut check: 4,000-Person study links diet, genes, and stomach troubles
Knowledge-focused ENROLLING_BY_INVITATIONThis study looks at how diet, genetics, and gut bacteria work together to cause digestive problems like IBS, IBD, and celiac disease. Researchers will follow about 4,000 adults with and without these conditions to find patterns. The goal is to understand why some people get sick …
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC
-
CT scans reveal hidden hernia recurrences after surgery
Knowledge-focused ENROLLING_BY_INVITATIONThis study follows 200 adults who had laparoscopic repair of a large hiatal hernia with mesh and anterior fundoplication. One year after surgery, participants get a CT scan to check for hernia recurrence, and their symptoms and quality of life are assessed. The goal is to compare…
Sponsor: Prof Urs Zingg • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
Frailty check could predict chemo danger for seniors
Knowledge-focused ENROLLING_BY_INVITATIONThis study looks at how frailty—a state of weakness and reduced physical function—affects the risk of severe side effects from chemotherapy in people aged 70 and older with cancer. Researchers will assess 160 patients using various tests for frailty, muscle loss, and overall heal…
Sponsor: Azienda Socio Sanitaria Territoriale Ovest Milanese, Ospedale di Legnano • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:04 UTC
-
Blood pressure drug may boost cancer therapy in stomach cancer patients
Knowledge-focused OngoingThis study looks at 80 patients with both locally advanced gastric cancer and high blood pressure. Researchers want to see if taking beta-blockers (a common blood pressure drug) alongside standard cancer treatment leads to better tumor shrinkage compared to other blood pressure d…
Sponsor: Nanfang Hospital, Southern Medical University • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Scientists decode genetic clues linking stomach bug to cancer
Knowledge-focused OngoingThis study looks at genetic changes in people with H. pylori infection or stomach cancer to understand how the infection can lead to cancer. Researchers will analyze tissue samples from 110 adults undergoing endoscopy. The goal is to find early warning signs and possible ways to …
Sponsor: Weill Medical College of Cornell University • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Can a special PET scan unlock a new way to treat Hard-to-Treat upper GI cancers?
Knowledge-focused OngoingThis study is testing whether a special PET scan using a tracer called 68Ga-PSMA can identify patients with advanced upper digestive tract cancers (like stomach or esophageal cancer) who might be eligible for a type of targeted radiation therapy called endoradiotherapy. The resea…
Phase: PHASE2 • Sponsor: Centre de recherche du Centre hospitalier universitaire de Sherbrooke • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:39 UTC
-
Anemia's hidden impact on blood flow during surgery revealed
Knowledge-focused ENROLLING_BY_INVITATIONThis study looks at how anemia changes blood flow in the smallest blood vessels (microcirculation) in patients having open surgery for gastric cancer. Researchers will compare 27 anemic patients with 27 non-anemic patients, all receiving standard goal-directed fluid therapy. They…
Sponsor: Fudan University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC
-
Can a Tumor's 'Neighborhood' predict drug success?
Knowledge-focused OngoingThis study reviews medical records from 300 cancer patients to see if the makeup of a tumor's surroundings (the tumor microenvironment) is linked to how well antibody-based therapies work. Researchers will analyze tissue samples and blood markers from patients with seven types of…
Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
Massive biobank aims to unlock Cancer's secrets
Knowledge-focused OngoingThis study collects tissue and blood samples from 1,600 people with various advanced cancers, along with their medical information, over the course of their treatment. Researchers will store these samples and data in a biobank for current and future studies. The goal is to better…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
Personalized blood test aims to track stomach and colon cancer spread
Knowledge-focused TerminatedThis study is for people with gastrointestinal cancer that has spread to the lining of the abdomen. Researchers will collect tumor tissue and blood samples to create a custom blood test that looks for cancer DNA. The goal is to see if this test can help doctors monitor the cancer…
Phase: NA • Sponsor: Rutgers, The State University of New Jersey • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Blood test may guide Post-Surgery cancer treatment
Knowledge-focused OngoingThis study follows 197 people with stage II-III gastric cancer who had surgery. Researchers want to see if using a blood test (ctDNA) to guide post-surgery treatment works as well as standard chemotherapy. The goal is to learn if some patients can safely receive less intense trea…
Sponsor: Qilu Hospital of Shandong University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
New study aims to uncover hidden health risks in 9/11 heroes
Knowledge-focused ENROLLING_BY_INVITATIONThis study looks at 200 male FDNY rescue workers who were exposed to dust and toxins after the World Trade Center attacks. Many developed acid reflux, which can lead to Barrett's esophagus and even cancer. Researchers will use simple, noninvasive tests like saliva samples and que…
Sponsor: NYU Langone Health • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
Sugar showdown: which sweetener wreaks havoc on your gut?
Knowledge-focused OngoingThis study gives 20 healthy adults drinks containing sucrose (table sugar), glucose, fructose, or plain water, then measures how their bodies respond. Researchers track gut hormones, blood sugar, digestion speed, and other health markers. The goal is to understand the unique effe…
Phase: NA • Sponsor: University Hospital, Basel, Switzerland • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
Massive data dive aims to improve GI care
Knowledge-focused ENROLLING_BY_INVITATIONThis study is a registry that will review medical records of 1,000 patients treated for benign or malignant gastrointestinal diseases between 2005 and 2030. Researchers will look at survival, symptoms like heartburn and swallowing trouble, and quality of life. The goal is to lear…
Sponsor: Methodist Health System • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Belly camera may help stomach cancer patients get the right treatment
Knowledge-focused ENROLLING_BY_INVITATIONThis study looks at whether using a small camera (laparoscopy) to see if stomach cancer has spread inside the belly can help doctors choose the best treatment. About 968 people with stage III stomach cancer will be randomly assigned to either standard care or care guided by this …
Phase: NA • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC
-
Massive GERD study tracks which treatment works best Long-Term
Knowledge-focused OngoingThis study follows 2,500 people with gastroesophageal reflux disease (GERD) to compare how well medications and surgery work over time. Researchers will track quality of life, heartburn symptoms, and patient satisfaction. The goal is to identify who benefits most from each treatm…
Sponsor: University of Pittsburgh • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC
-
Adding stomach scope to colonoscopy: worth the cost?
Knowledge-focused OngoingThis study examines the extra costs of doing an upper endoscopy (stomach scope) at the same time as a routine colonoscopy for colon cancer screening. Researchers will also analyze the overall economic burden of treating stomach cancer. Data from 250 patients will be collected fro…
Sponsor: Unidade Local De Saúde Do Norte Alentejano • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:06 UTC
-
French study tracks Real-World success of combo therapy for stomach cancer
Knowledge-focused OngoingThis study observes 208 adults in France with advanced or metastatic stomach, esophageal, or gastroesophageal junction cancer who are receiving nivolumab combined with chemotherapy as their first treatment. Researchers will track how long patients live and how their disease progr…
Sponsor: Bristol-Myers Squibb • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:04 UTC
-
Your teeth might reveal cancer risk: new study investigates
Knowledge-focused OngoingThis pilot study is looking at whether dental erosion (loss of tooth enamel) could be a non-invasive biomarker for esophagogastric cancer and other cancers. Researchers will survey 174 participants (cancer patients and healthy volunteers) about diet, habits, and GERD symptoms, an…
Phase: NA • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
Tumor DNA study aims to unlock secrets of drug resistance
Knowledge-focused OngoingThis study collects tumor tissue, blood, and saliva from 2500 people with various solid cancers to analyze their genetic makeup. The goal is to understand why some tumors become resistant to targeted therapies. Samples may also be grown in special mice to study how genetics affec…
Sponsor: Fondazione del Piemonte per l'Oncologia • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:03 UTC
-
New national registry aims to improve care for rare genetic polyposis syndromes
Knowledge-focused OngoingThis study is a national registry collecting data from 1500 people with familial adenomatous polyposis (FAP) and related conditions across 28 Italian centers. It aims to better understand how these diseases progress, how they are currently managed, and what factors influence outc…
Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:00 UTC
-
AI tool aims to predict dangerous leak after stomach cancer surgery
Knowledge-focused OngoingThis study is testing whether an artificial intelligence model can predict duodenal stump leakage, a serious complication that can occur after laparoscopic surgery to remove stomach cancer. The research involves 1200 participants who have had or will have this surgery. The goal i…
Sponsor: Jichao Qin • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:00 UTC
-
Ear zaps aim to tame stomach troubles
Knowledge-focused OngoingThis study tests whether electrically stimulating a nerve in the ear can reach the internal vagus nerve, which controls stomach function. Researchers will measure nerve signals and stomach activity in 131 healthy volunteers and people with gastroparesis. The goal is to see if thi…
Phase: NA • Sponsor: Indiana University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:11 UTC
-
Scientists probe nerve signals during stomach stimulation
Knowledge-focused OngoingThis study looks at how a device that electrically stimulates the stomach (gastric electrical stimulation) affects the vagus nerve and heart in people with gastroparesis, a condition where the stomach empties slowly. Researchers will measure heart rate variability and hormone lev…
Sponsor: Indiana University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:10 UTC
-
Scientists dig into past cases to find best brain tumor treatments for stomach cancer patients
Knowledge-focused OngoingThis study reviews medical records from 230 adults with stomach or esophagus cancer that spread to the brain. Researchers want to see which local treatments (like surgery or radiation) worked best and how long patients lived. The goal is to gather information to help doctors make…
Sponsor: Blokhin's Russian Cancer Research Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:10 UTC
-
Scientists map nerve signals to improve gastric stimulation for stomach paralysis
Knowledge-focused OngoingThis study looks at how the vagus nerve works in people with gastroparesis (stomach paralysis) who have a gastric electrical stimulator implanted. Researchers will use a non-invasive electrode patch on the neck to measure nerve signals and see if they relate to symptom relief. Th…
Sponsor: Indiana University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:10 UTC
-
3D-Printed tumors could revolutionize liver cancer drug matching
Knowledge-focused OngoingThis study explores whether 3D bioprinting can create personalized models of liver cancer from a patient's own tumor tissue. Researchers will test different drugs on these models to see which ones work best, aiming to predict a patient's response before treatment. The goal is to …
Sponsor: Peking Union Medical College Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:09 UTC
-
New study aims to improve survival in advanced stomach cancer
Knowledge-focused OngoingThis study looks back at 300 people with advanced stomach or gastroesophageal junction cancer to see how different treatments before and after surgery affect survival. The goal is to find out which treatment plans work best and whether tumor shrinkage after pre-surgery therapy pr…
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:08 UTC
-
No-Cut reflux fix under the microscope: 500 patients watched for years
Knowledge-focused ENROLLING_BY_INVITATIONThis study is not testing a new treatment. Instead, it follows 500 people who already had a procedure called TIF (transoral incisionless fundoplication) for acid reflux. Researchers will collect data from medical records to see how symptoms and quality of life change over time. T…
Sponsor: Indiana University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:08 UTC
-
Chilly or cozy? study tests best temperature for tube feeding in ICU
Knowledge-focused ENROLLING_BY_INVITATIONThis study looks at whether cold or warm liquid food given through a tube affects how fast the stomach empties in adult intensive care patients. Researchers will measure stomach volume over time and check for issues like vomiting or diarrhea. The goal is to find out which tempera…
Phase: NA • Sponsor: Bursa Yuksek Ihtisas Training and Research Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:06 UTC
-
Age matters: new study looks at stomach cancer treatment choices
Knowledge-focused OngoingThis study looks at how a patient's age influences the type of treatment they receive for stomach cancer that can be removed with surgery, and how that affects their survival. Researchers will analyze genetic information from tumors to better understand why age matters. The goal …
Sponsor: P. Herzen Moscow Oncology Research Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:04 UTC
-
AI assistant for cancer diagnosis: will it help doctors spot tumors better?
Knowledge-focused ENROLLING_BY_INVITATIONThis study tests whether an artificial intelligence (AI) model can help pathologists diagnose gastric cancer more accurately and quickly. About 1000 patients with gastric biopsies or surgical samples will take part. Some pathologists will use the AI tool to assist their diagnosis…
Phase: NA • Sponsor: Nanfang Hospital, Southern Medical University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:03 UTC
-
Study tests glucagon doses for Post-Surgery low blood sugar
Knowledge-focused OngoingThis study looks at how different doses of glucagon, a natural hormone that raises blood sugar, affect people who have low blood sugar after weight-loss surgery. Researchers will give 28 participants several doses of glucagon and measure their blood sugar and hormone levels. The …
Phase: PHASE4 • Sponsor: Joslin Diabetes Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC
-
Researchers track recovery after keyhole surgery for swallowing disorders
Knowledge-focused OngoingThis study follows 200 patients who had minimally invasive surgery for conditions like achalasia, GERD, or hiatal hernia. Each year, patients fill out questionnaires about their symptoms and quality of life, and doctors review their medical records. The goal is to understand how …
Sponsor: Ottawa Hospital Research Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:00 UTC
-
Cancer biobank study aims to unlock secrets of immunotherapy resistance
Knowledge-focused TerminatedThis observational study collects blood and tumor tissue samples from people with gastroesophageal cancer to study genetic changes that may cause resistance to immunotherapy. It does not involve any treatment or experimental drugs. The goal is to identify new targets for future i…
Sponsor: Duke University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:00 UTC
-
Longer breathing tube after surgery may cut risks for sleep apnea patients
Knowledge-focused ENROLLING_BY_INVITATIONThis study looks at whether leaving a breathing tube in for 24-48 hours after gastric cancer surgery can lower complications in patients who also have severe obstructive sleep apnea. Researchers will compare two groups of 240 patients: one with standard tube removal and one with …
Sponsor: Qilu Hospital of Shandong University • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:13 UTC
-
Heated chemo during surgery: does it slow down gut recovery?
Knowledge-focused OngoingThis study looks back at 193 people with stomach, appendix, or colon cancer who had surgery with or without heated chemotherapy (HIPEC). Researchers want to see if HIPEC affects how quickly the bowels start working again after surgery and whether it leads to more complications. T…
Sponsor: Peking University People's Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:12 UTC
-
Cancer tissue bank aims to fuel future discoveries
Knowledge-focused OngoingThis study collects leftover tissue, blood, and other fluid samples from 6,000 people with benign or malignant tumors of the soft tissue, gastrointestinal tract, or abdomen. Researchers will use these samples in lab studies to better understand the causes, prevention, diagnosis, …
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC
-
120,000-Person study hopes to crack the code of chronic illness
Knowledge-focused TerminatedThis observational study plans to enroll 120,000 people with various chronic diseases like pancreatitis, diabetes, and arthritis. Researchers will collect blood samples and health data to study how genetics and lifestyle affect disease progression. The goal is to find common dise…
Sponsor: University of Pittsburgh • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:08 UTC
-
Thousands of heartburn patients to be tracked for years in major new study
Knowledge-focused ENROLLING_BY_INVITATIONThis study is creating a large registry of 2,000 people with gastroesophageal reflux disease (GERD) and related conditions like Barrett's esophagus. Researchers will collect data from medical records and questionnaires over 5 years to better understand the disease and its treatme…
Sponsor: Johns Hopkins University • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:05 UTC
-
Tiny tools, big promise: endoscopic procedures take on major GI surgery
Knowledge-focused ENROLLING_BY_INVITATIONThis study tracks 500 adults with conditions like acid reflux, achalasia, or complications after weight-loss surgery. Participants choose either a newer endoscopic procedure (done through a scope) or standard surgery. Researchers will compare how well each approach controls sympt…
Phase: NA • Sponsor: University of California, Davis • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:02 UTC
-
500 obese adults donate samples to unlock secrets of weight loss
Knowledge-focused OngoingThis study collects blood, urine, and tissue samples from 500 obese adults to help researchers understand why people gain weight, lose weight, or regain weight after treatment. Participants must be over 18 with a BMI of 30 or higher. The samples will be stored for up to 10 years …
Sponsor: Pichamol Jirapinyo, MD, MPH • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:01 UTC
-
1,000 patients join hunt for stomach cancer early warning signs
Knowledge-focused ENROLLING_BY_INVITATIONThis study follows 1,000 people with stomach pre-cancer conditions like chronic gastritis and intestinal metaplasia. Researchers will track disease progression over time and analyze biospecimens to find biomarkers linked to cancer development. The goal is to better understand who…
Sponsor: University of California, Davis • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:01 UTC
-
500 patients join new GI registry to uncover hidden causes of stomach troubles
Knowledge-focused ENROLLING_BY_INVITATIONThis study is creating a registry of 500 adults with functional GI disorders like IBS and chronic constipation. Researchers will collect medical data, diet and lifestyle questionnaires, and biological samples to explore genetic, microbial, and environmental factors. The goal is t…
Sponsor: Massachusetts General Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:56 UTC
-
Zapping the brain to calm the gut: a new frontier for IBS?
Knowledge-focused OngoingThis study tests whether non-invasive brain stimulation (rTMS) can alter gut activity in healthy people and those with functional dyspepsia or IBS. Researchers will measure stomach rhythms, heart rate, and fullness thresholds after applying rTMS to the motor cortex. It is an earl…
Phase: NA • Sponsor: David Levinthal • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:56 UTC
-
Throat reflux study withdrawn before enrolling any patients
Knowledge-focused TerminatedThis study aimed to develop better diagnostic tests and a device (external pressure on the throat) for patients with pharyngeal reflux, where stomach contents reach the throat. It planned to include adults with GERD and throat symptoms. However, the study was withdrawn before enr…
Phase: NA • Sponsor: Medical College of Wisconsin • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:54 UTC
-
Pill-Sized camera reveals hidden stomach damage from common painkillers
Knowledge-focused TerminatedThis study uses a magnetically-controlled capsule (a tiny camera you swallow) to look at stomach damage caused by long-term use of NSAID painkillers like ibuprofen. Researchers will compare stomach images from 180 people who take NSAIDs with those who don't. The goal is to better…
Sponsor: Shanghai Jiao Tong University School of Medicine • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:52 UTC
-
8-year study reveals which weight-loss surgery is kinder to your esophagus
Knowledge-focused ENROLLING_BY_INVITATIONThis study follows 75 people who had either sleeve gastrectomy or gastric bypass for severe obesity. Researchers track acid reflux symptoms, esophageal damage, and other measures for 8 years using tests like endoscopy and pH monitoring. No new treatments are given—it's purely obs…
Sponsor: Clinica Gastrobese • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:51 UTC
-
Can better eating keep older stomach cancer patients stronger?
Knowledge-focused ENROLLING_BY_INVITATIONThis study follows 438 older adults (60+) who had surgery for gastric cancer. Researchers want to understand how diet changes over time and how those changes relate to frailty. Participants complete surveys at discharge and at 1, 3, and 6 months after surgery. The goal is to desi…
Sponsor: Nanjing Medical University • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:51 UTC
-
Gastroparesis procedure prediction study pulled before starting
Knowledge-focused TerminatedThis study aimed to find out if two tests—EndoFLIP and antroduodenal manometry—could predict which patients with severe gastroparesis would benefit from a procedure called G-POEM. The plan was to measure stomach muscle activity and pressure before the procedure. However, the stud…
Phase: NA • Sponsor: Northwestern University • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:51 UTC
-
Gender gap in stomach cancer care revealed in massive german study
Knowledge-focused OngoingThis study examines whether men and women with gastric cancer receive different care in Germany. Researchers will analyze data from 75,000 patients treated between 2017 and 2021, looking at survival rates, complications, and treatment approaches. The goal is to identify gender-ba…
Sponsor: Medizinische Hochschule Brandenburg Theodor Fontane • Aim: Knowledge-focused
Last updated Jun 26, 2026 18:12 UTC
-
Medical students under the microscope: GERD, stress, and eating habits examined
Knowledge-focused OngoingThis study surveys over 3,700 medical students and interns across the Middle East to find out how many have gastroesophageal reflux disease (GERD). It also looks at how eating habits, stress, anxiety, and depression relate to GERD and how the condition affects their quality of li…
Sponsor: Zagazig University • Aim: Knowledge-focused
Last updated Jun 26, 2026 16:46 UTC
-
Study tracks reflux after sleeve gastrectomy: who gets better, who gets worse?
Knowledge-focused OngoingThis study followed 64 adults who had laparoscopic sleeve gastrectomy (a common weight-loss surgery) to see how acid reflux symptoms changed. Researchers compared those who had reflux before surgery with those who did not. They used a standard questionnaire to measure heartburn a…
Sponsor: Korea University Anam Hospital • Aim: Knowledge-focused
Last updated Jun 26, 2026 13:30 UTC
-
Popular Weight-Loss drugs may change Pre-Surgery fasting rules
Knowledge-focused ENROLLING_BY_INVITATIONThis study looks at how GLP-1 receptor agonists (like Ozempic or Wegovy) affect how fast the stomach empties before surgery. These drugs are used for weight loss and diabetes, but they slow stomach emptying, which could raise the risk of food or liquid entering the lungs during a…
Sponsor: Wael Saasouh, MD • Aim: Knowledge-focused
Last updated Jun 26, 2026 13:18 UTC